Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04711161 2024-01-23

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Phase 1 Suspended

73 enrolled

Gynecologic

Ovarian Neoplasms

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Phase 1 Suspended

21 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02093871 2017-07-21

PISH-2

Phase 1 Suspended

20 enrolled

Gynecologic

Hyperthermia, Ovarian Neoplasms

NCT00753480 2008-11-07

A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Suspended

56 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PISH-2

A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer